Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation
Medtronic plc received FDA approval for the DiamondTemp™ Ablation (DTA) system, a temperature-controlled, irrigated RF ablation system for treating recurrent, symptomatic paroxysmal atrial fibrillation (AF) unresponsive to drug therapy. The DTA system, featuring industrial-grade diamonds for enhanced thermal conductivity, offers procedural efficiencies and safety. The DIAMOND-AF trial demonstrated its effectiveness and safety, with significant procedural advantages over conventional systems.
Reference News
Medtronic plc received FDA approval for the DiamondTemp™ Ablation (DTA) system, a temperature-controlled, irrigated RF ablation system for treating recurrent, symptomatic paroxysmal atrial fibrillation (AF) unresponsive to drug therapy. The DTA system, featuring industrial-grade diamonds for enhanced thermal conductivity, offers procedural efficiencies and safety. The DIAMOND-AF trial demonstrated its effectiveness and safety, with significant procedural advantages over conventional systems.